Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leprosy.

W M Meyers1

  • 1Armed Forces Institute of Pathology, Washington, DC.

Dermatologic Clinics
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Advances in leprosy research, driven by armadillo models, offer new diagnostic tools, vaccines, and multidrug therapies. Effective control requires chemotherapy, immunoprophylaxis, and improved socioeconomic conditions in endemic areas.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Study of names and folklore associated with Mycobacterium ulcerans infection in various endemic countries in Africa].

Medecine tropicale : revue du Corps de sante colonial·2007
Same author

Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity.

Tropical medicine & international health : TM & IH·2004
Same author

Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease.

Infection and immunity·2003
Same author

Anti-leprosy protective vaccination of rhesus monkeys with BCG or BCG plus heat-killed Mycobacterium leprae: lepromin skin test results.

Leprosy review·2002
Same author

Prophylactic effect of mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer).

Clinical and diagnostic laboratory immunology·2002
Same author

Characterization of an unusual Mycobacterium: a possible missing link between Mycobacterium marinum and Mycobacterium ulcerans.

Journal of clinical microbiology·2002
Same journal

The Evidence Is In: Devices and Biologics Reshaping Modern Dermatology.

Dermatologic clinics·2026
Same journal

Energy-Based Devices for Body Contouring.

Dermatologic clinics·2026
Same journal

Microfocused Ultrasound with Visualization for Skin Tightening: Clinical Applications, Safety, and Technical Considerations.

Dermatologic clinics·2026
Same journal

Devices in Onychomycosis: A Status Update.

Dermatologic clinics·2026
Same journal

Acne Laser Devices in Dermatology.

Dermatologic clinics·2026
Same journal

Fractional Laser Therapy for Androgenetic Alopecia: Mechanisms, Clinical Evidence, and Practical Implementation.

Dermatologic clinics·2026
See all related articles

Area of Science:

  • Immunology
  • Microbiology
  • Infectious Diseases

Background:

  • Leprosy transmission primarily occurs via the nasorespiratory route, with rare transplacental infections.
  • Contact with M. leprae-infected armadillos is a potential transmission source.
  • Defective cell-mediated immunity (CMI), particularly lymphocyte-macrophage interactions and T-cell imbalances, characterizes leprosy.

Purpose of the Study:

  • To summarize recent advances in leprosy research, including diagnostics, vaccines, and therapeutics.
  • To discuss the immunologic basis of leprosy and potential immunotherapeutic strategies.
  • To outline current and future approaches to leprosy management and control.

Main Methods:

  • Utilizing M. leprae from armadillos for in vitro drug testing and immunologic studies.

Related Experiment Videos

  • Analyzing T-cell populations and cytokine infiltration in leprosy lesions.
  • Evaluating immunotherapeutic vaccines (killed M. leprae-plus-BCG) and immunoprophylactic vaccine trials.
  • Assessing multidrug regimens and experimental drugs for leprosy treatment.

    • Main Results:

    • Vaccination with killed M. leprae-plus-BCG stimulates CMI and clears bacilli in lepromatous patients, indicating immunotherapeutic potential.
    • Multidrug regimens (dapsone, rifampin, clofazimine/thioamide) are now standard due to dapsone resistance.
    • Monitoring M. leprae-specific antigens and antibodies can assess treatment response in multibacillary leprosy.
    • No clear evidence links AIDS and leprosy interactions.

    Conclusions:

    • Chemotherapy is the primary hope for leprosy control, but effective immunoprophylaxis and socioeconomic improvements are crucial for eradication.
    • Multidrug therapy reduces leprosy incidence, while ongoing vaccine trials offer future prevention possibilities.
    • Further research into immunologic dysfunction and therapeutic interventions is vital for combating leprosy.